Innospec Revenue Growth Accelerates as Cash Flow Tightens
Innospec posted second-quarter revenue of $491.4 million, up 12% from a year earlier and well ahead of the 3% pace set in the first quarter.
Innospec (IOSP) reported second-quarter revenue of $491.4 million, up 12% from a year earlier, a sharp acceleration from the 3% growth logged in the first quarter, when winter storm damage shut down plants in North Carolina. The specialty chemicals maker's rebound was broad enough to lift GAAP operating income 16% to $39.7 million, though the first-half total of $76.2 million still trailed the $76.8 million posted in the same period of 2024, a reminder of how much ground the January quarter cost the company.
The recovery centered on Performance Chemicals, where revenue rose 9% to $190.3 million after the North Carolina shutdowns had limited first-quarter growth to just 1%. Segment operating income jumped 15% to $16.4 million, reversing a 46% first-quarter decline, and gross margin held nearly flat year over year at 17.3%, a marked improvement from the 4.2-point margin erosion the segment absorbed three months earlier. The mix within Performance Chemicals also shifted: volumes fell 2% in the quarter while price and mix contributed 8 points of growth, compared with a year earlier when volumes were rising and pricing added little, a sign the segment is now leaning on price to offset softer demand.
Fuel Specialties told a different story. Revenue there grew 12% to $185.7 million, accelerating from 7% growth in the first quarter and driven mainly by a 7% rise in volumes. But gross margin compressed 1.5 points to 36.6%, the segment's first margin decline after several quarters of flat-to-expanding margins near the top of its target range, and operating income growth slowed to 3% at $36.3 million, well below the double-digit gains posted as recently as the third quarter of 2024. Oilfield Services provided the clearest turnaround, with revenue up 14% to $115.4 million, gross margin expanding 2.7 points to 32.3% and operating income climbing 40% to $8.7 million, a reversal from the weak Middle East activity that had pressured the segment a year earlier.
Corporate costs continued to creep higher, reaching $21.6 million in the quarter versus $20.9 million a year ago and pushing the first-half total to $43.9 million from $38.6 million. The effective tax rate eased to 25.0% from 26.0%, a modest offset. Adjusted non-GAAP earnings per share rose sequentially to $1.27 from $1.05 in the first quarter but were roughly flat against the $1.26 posted a year earlier, and adjusted EBITDA of $50.1 million was up just 2% year over year, leaving the first-half total of $93.8 million down 9% from $103.1 million in the same period of 2024.
The income statement recovery did not carry through to cash generation. Operating cash flow fell to $7.2 million in the quarter, down from $17.6 million in the first quarter and far below the $61.4 million generated in the fourth quarter of 2024, as working capital consumed $60.9 million in the first half versus $22.6 million a year earlier. Net cash fell to $250.2 million at quarter-end from $289.1 million three months earlier, despite the company remaining profitable throughout.
Innospec repurchased $6.4 million of stock in the quarter, covering 87,089 shares, below the $8.2 million bought back in the second quarter of 2024 and the $10.7 million repurchased in the third quarter of last year, though the diluted share count still shrank to 24.7 million from 25.0 million a year earlier. The quarter carried none of the special charges that weighed on results in late 2024, when $42.9 million of impairment and restructuring costs tied to the QGP business and the exit from U.S. stimulation services hit the income statement, leaving the current period's results free of one-time drag even as working capital consumed the cash that operating income produced.